Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRAS^G13D colorectal cancer.

ABSTRACT: Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, with KRAS mutations playing a significant role in its tumorigenesis. Among the KRAS variants, the G13D mutation is associated with poor prognosis and distinctive biological behaviors. This study focuses on the role of HER2, a critical prognostic and predictive biomarker, in modulating the unique characteristics of KRAS^G13D-mutated CRCs. We identified a novel transcriptional regulatory network involving HER2, ELF3, and KRAS, with ELF3 acting as a key transcription factor (TF) that regulates KRAS expression under conditions of HER2 overexpression. Our findings reveal that this HER2-ELF3-KRAS axis is exclusively activated in KRAS^G13D, driving aggressive oncogenic features and conferring resistance to

SUBMITTER: Hwang SY 

PROVIDER: S-EPMC12063335 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature